Glaucoma is the leading cause of irreversible blindness. The most successful way to prevent vision loss from glaucoma is to lower intraocular pressure with filtration surgery. This surgery shunts fluid out of the eye through a channel created during a trabeculectomy procedure or by a transscleral drainage device placed during Minimally Invasive Glaucoma Surgery (MIGS). Despite compelling therapeutic advantages over nonsurgical treatments, drainage surgery and devices are clinically limited by post-operative scarring.
The RadianceTx Beta Ophthalmic Applicator System is a device solution designed to topically apply beta therapy to the bleb reservoirs following trabeculectomy or MIGS drainage device insertion.
Validated in three clinical studies conducted by preeminent ophthalmic research teams, beta therapy has been shown to improve glaucoma filtration surgery outcomes. A recent study in trabeculectomy reported odds ratios that beta irradiation therapy patients were five and a half times more likely to experience lower IOP at the end of 1 year than patients treated with the current standard of care antimetabolite mitomycin-C.